what has already been shown. The discrepancy observed between the two methods highlights the importance of access to biological methods. The identified risk factors will through regular evaluation, better identify PLWHA at greater risk of non-compliance and to offer enhanced compliance support.
Introduction Following the emergence of lymphogranuloma venereum (LGV) proctitis in the Netherlands in 2003, a voluntary surveillance system for LGV has been established in France. Based on the data of the National Reference Centre (NRC) for chlamydiae, Bordeaux, France, this study aimed to describe the epidemiology of LGV and non-LGV ano-rectal infection in France and to examine the characteristics of affected populations. Methods The French surveillance network includes clinicians, biologists and NRC. Biologists sent rectal CT-positive samples to the NRC where the strains were typed by using two realtime PCR targeting pmpH gene specific of L and L2b strains. Biologists and clinicians performed a document on patient's clinical, biological and behavioural data. Clinical, biological and sexual risk behavioural variables were compared in men with LGV and with non-LGV cases according the HIV status using appropriate statistical tests over the period [2010] [2011] [2012] [2013] [2014] [2015] . LGV continues to affect a core group: HIV-infected MSM who engage in high-risk sexual practices. They were older and more often infected with syphilis than men with non-LGV cases, were usually symptomatic and mainly lived in Paris. Those who acquired LGV reinfection had concurrent hepatitis C and syphilis more often than those with a single episode. Conclusion A steady annual increase in the number of LGV cases and in the number of LGV recurrences was observed since 2012, demonstrating that the LGV epidemic is not under control and requires providing better information about the disease to affected patients and physicians of all specialties who take care them
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QUANTIFICATION OF THE RISK OF PELVIC INFLAMMATORY DISEASE FOLLOWING A CHLAMYDIA TRACHOMATIS TEST BY DIAGNOSTIC TEST TYPE
Introduction Nucleic Acid Amplification Tests (NAATs) are the recommended test type for diagnosing Chlamydia trachomatis (chlamydia). However poorer performing methods remain in use. We compared the risk of pelvic inflammatory disease (PID) in women tested for chlamydia by diagnostic test type. Methods We used a sub-set of the Danish Chlamydia study that included all female residents of Denmark who were tested for chlamydia (1998) (1999) (2000) (2001) when aged 15-34 years. Chlamydia tests performed on urinary or genital samples with a definitive positive or negative result were categorised as non-NAAT (ELISA; IF; "antigen") or NAAT (PCR; SDA; TMA; LCR; DNA/RNA) and limited to each woman's first test. Test records were linked to hospital presentations for PID within 12 months. Women with previous PID or PID diagnosed on the same date as the test were excluded. We used logistic regression to compare the risk of PID by test type adjusted for age, test year and test result. Results Of the 2 72 105 women in the study, 44.78% were tested using NAAT, 6.38% tested positive for chlamydia and 0.64% were diagnosed with PID within 12 months. Overall, the adjusted risk of PID within 12 months of a chlamydia test was higher following a positive test (AOR 1.40 (95%CI 1.18-1.67) and in older women (25-34 years 1.36 (1.23-1.49)) and lower in women tested using a ) and in the more recent time interval (2000/2001 0.89 (0.80-0.99) ). In women with a positive test, and presumably treated infection, the risk of PID did not differ by test type (1.25 (0.87-1.79)). In women with a negative test, the risk of PID was lower following a ). Conclusion Women with a negative result from a non-NAAT chlamydia test have a 16% higher risk of PID by 12 months compared to women with a negative result from a NAAT. This is presumably due to the increased proportion of false negative tests with the less sensitive non-NAATs. This study quantifies the health impact of using poorer performing chlamydia diagnostic tests and provides further evidence for phasing them out.
